

# Clinical Trial Protocol

## Iranian Registry of Clinical Trials

02 Jun 2026

### Comparing the Effect of Sevelamer Hydrochloride and Calcium Carbonate on Serum Level of hs-CRP, Soluble CD-14 and Endotoxin in Hemodialysis Patients

#### Protocol summary

##### Study aim

The effect of Sevelamer Hydrochloride and Calcium Carbonate on serum level of hs-CRP, soluble CD-14, and endotoxin in hemodialysis patients will be studied.

##### Design

Randomized clinical trial on two parallel groups, without blinding, phase 4 on 50 patients, which will use Rand list software for randomization.

##### Settings and conduct

The present study will be performed on hemodialysis patients referred to Imam Reza Hospital of Tabriz University of Medical Sciences. Patients will be randomly divided into two equal groups and will be intervened for two months. At the end of the study, the levels of endotoxin, sCD-14 and hs-CRP will be examined.

##### Participants/Inclusion and exclusion criteria

Inclusion criteria are age over 18 years old, end-stage renal disease, hemodialysis for more than three months and indication for treatment with phosphate binders. Also non-inclusion criteria are impossibility of alternative treatment with Sevelamer Hydrochloride or Calcium Carbonate, history of any substance abuse, history of immunological diseases, any cancer, recent active infection, history of previous kidney transplantation and history of receiving immunosuppressive therapy.

##### Intervention groups

Patients in group A will receive Sevelamer Hydrochloride 800 mg tablets 3 times daily with meals for 2 months and group B patients will receive Calcium Carbonate 1000 mg tablets 3 times daily with meals for 2 months.

##### Main outcome variables

The primary outcomes of the present study are serum levels of endotoxin; sCD-14 and hs-CRP. Also the secondary outcome of the present study is possible side effects of each drug.

#### General information

##### Reason for update

##### Acronym

##### IRCT registration information

IRCT registration number: **IRCT20200724048193N1**

Registration date: **2020-11-15, 1399/08/25**

Registration timing: **registered\_while\_recruiting**

Last update: **2020-11-15, 1399/08/25**

Update count: **0**

##### Registration date

2020-11-15, 1399/08/25

##### Registrant information

##### Name

Shabnam Salehi

##### Name of organization / entity

##### Country

Iran (Islamic Republic of)

##### Phone

+98 41 3380 5677

##### Email address

salehish@tbzmed.ac.ir

##### Recruitment status

**Recruitment complete**

##### Funding source

##### Expected recruitment start date

2020-10-22, 1399/08/01

##### Expected recruitment end date

2020-11-21, 1399/09/01

##### Actual recruitment start date

empty

##### Actual recruitment end date

empty

##### Trial completion date

empty

**Scientific title**

Comparing the Effect of Sevelamer Hydrochloride and Calcium Carbonate on Serum Level of hs-CRP, Soluble CD-14 and Endotoxin in Hemodialysis Patients

**Public title**

Comparing the Effect of Sevelamer Hydrochloride and Calcium Carbonate on Serum Level of Inflammatory Markers in Hemodialysis Patients

**Purpose**

Treatment

**Inclusion/Exclusion criteria****Inclusion criteria:**

Patients with ESRD Indication of treatment with phosphate binders Hemodialysis preformation for more than three months

**Exclusion criteria:**

Impossibility of alternative treatment with Sevelamer Hydrochloride or Calcium Carbonate Cigarette, alcohol and drug abuse History of immunological diseases Any type of cancer Recent active infection Previous kidney transplant history History of receiving immunosuppressive treatment

**Age**

From **18 years** old

**Gender**

Both

**Phase**

4

**Groups that have been masked**

*No information*

**Sample size**

Target sample size: **40**

**Randomization (investigator's opinion)**

Randomized

**Randomization description**

Randomization will be done using Rand list software version 1.2 based on patients' file numbers and creating a random number table. Patients will be randomly divided into two equal groups and randomly assigned to the Sevelamer Hydrochloride or Calcium Carbonate group.

**Blinding (investigator's opinion)**

Not blinded

**Blinding description****Placebo**

Not used

**Assignment**

Parallel

**Other design features****Secondary Ids**

empty

**Ethics committees****1****Ethics committee****Name of ethics committee**

Ethics Committee of Tabriz University of Medical

Sciences

**Street address**

6th floor, No.116, 7th Sahand Alley, Sahand Blvd, Tabriz, Iran.

**City**

Tabriz

**Province**

East Azarbaijan

**Postal code**

5168643619

**Approval date**

2015-08-24, 1394/06/02

**Ethics committee reference number**

TBZMED.REC.1394.470

**Health conditions studied****1****Description of health condition studied**

End Stage Renal Disease

**ICD-10 code**

I13.11

**ICD-10 code description**

Hypertensive heart and chronic kidney disease without heart failure, with stage 5 chronic kidney disease, or end stage renal disease

**Primary outcomes****1****Description**

Endotoxin

**Timepoint**

At the beginning of the study and two months after starting treatment

**Method of measurement**

Serum level measurement

**2****Description**

high-sensitivity C-reactive protein

**Timepoint**

At the beginning of the study and two months after starting treatment

**Method of measurement**

Serum level measurement

**3****Description**

Soluble CD-14

**Timepoint**

At the beginning of the study and two months after starting treatment

**Method of measurement**

Serum level measurement

## Secondary outcomes

### 1

#### Description

Possible side effects

#### Timepoint

Two months after starting treatment

#### Method of measurement

Assessment and questioning of the patient

## Intervention groups

### 1

#### Description

Intervention group: Receiving 800 mg Sevelamer Hydrochloride tablets product by Faran Shimi pharmaceutical 3 times a day with meal for 2 months

#### Category

Treatment - Drugs

### 2

#### Description

Intervention group: Receiving 500 mg Calcium Carbonate tablets product by Jalinous pharmaceutical at dose of 1000 mg 3 times a day with meal for 2 months

#### Category

Treatment - Drugs

## Recruitment centers

### 1

#### Recruitment center

##### Name of recruitment center

Emam Reza Hospital

##### Full name of responsible person

Shabnam Salehi

##### Street address

Emam Reza Hospital, Daneshgah Street, Daneshgah Square

##### City

Tabriz

##### Province

East Azarbaijan

##### Postal code

5166614756

##### Phone

+98 41 3337 3966

##### Email

salehish@tbzmed.ac.ir

## Sponsors / Funding sources

### 1

#### Sponsor

##### Name of organization / entity

Tabriz University of Medical Sciences

#### Full name of responsible person

Mohammad samiei

#### Street address

Third floor of Tabriz University of Medical Sciences  
Central Building, Golgasht Street, Tabriz

#### City

Tabriz

#### Province

East Azarbaijan

#### Postal code

5166614766

#### Phone

+98 41 3335 7310

#### Email

Samiei.moh@gmail.com

#### Grant name

#### Grant code / Reference number

#### Is the source of funding the same sponsor organization/entity?

Yes

#### Title of funding source

Tabriz University of Medical Sciences

#### Proportion provided by this source

100

#### Public or private sector

Public

#### Domestic or foreign origin

Domestic

#### Category of foreign source of funding

*empty*

#### Country of origin

#### Type of organization providing the funding

Academic

## Person responsible for general inquiries

#### Contact

##### Name of organization / entity

Tabriz University of Medical Sciences

##### Full name of responsible person

Shabnam Salehi

##### Position

Nephrologist

##### Latest degree

Subspecialist

##### Other areas of specialty/work

Internal Medicine

##### Street address

Emam Reza Hospital, Daneshgah Street, Daneshgah Square

##### City

Tabriz

##### Province

East Azarbaijan

##### Postal code

5166614756

##### Phone

+98 41 3337 3966

##### Email

salehish@tbzmed.ac.ir

## Person responsible for scientific inquiries

### Contact

**Name of organization / entity**

Tabriz University of Medical Sciences

**Full name of responsible person**

Shabnam Salehi

**Position**

Nephrologist

**Latest degree**

Subspecialist

**Other areas of specialty/work**

Internal Medicine

**Street address**

Emam Reza Hospital, Daneshgah Straat, Daneshgah Square

**City**

Tabriz

**Province**

East Azarbaijan

**Postal code**

5166614756

**Phone**

+98 41 3337 3966

**Email**

salehish@tbzmed.ac.ir

## Person responsible for updating data

### Contact

**Name of organization / entity**

Tabriz University of Medical Sciences

**Full name of responsible person**

Shabnam Salehi

**Position**

Nephrologist

**Latest degree**

Subspecialist

**Other areas of specialty/work**

Internal Medicine

**Street address**

Emam Reza Hospital, Daneshgah Street, Daneshgah Square.

**City**

Tabriz

**Province**

East Azarbaijan

**Postal code**

5166614756

**Phone**

+98 41 3337 3966

**Email**

salehish@tbzmed.ac.ir

## Sharing plan

**Deidentified Individual Participant Data Set (IPD)**

No - There is not a plan to make this available

**Justification/reason for indecision/not sharing IPD**

There is no further information.

**Study Protocol**

No - There is not a plan to make this available

**Statistical Analysis Plan**

No - There is not a plan to make this available

**Informed Consent Form**

No - There is not a plan to make this available

**Clinical Study Report**

No - There is not a plan to make this available

**Analytic Code**

No - There is not a plan to make this available

**Data Dictionary**

No - There is not a plan to make this available